Optional product analytics

With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.

ALNY · Published research archive | StockMarketAgent.AI

DiscoverOutlookToolsDevelopersCompany

ALNY · Archive

Read prior published editions, ratings, and price trends. Each row discloses its own analysis date.

2026May

ALNY May 2026 · Strong Buy

Alnylam is the pioneer in RNAi therapeutics, actively inflecting into sustained GAAP profitability. With a $665.75 base case fair value (+128% upside), the risk-reward is heavily skewed positive as the pipeline expands from rare to prevalent indications, validating its hyper-growth compounder archetype.Latest published research · analyzed 2026-05-13 · historical · sources unverified

Strong Buy

USD 292.03

StockMarketAgent

Methodologyv3.2

Product

Discover Coverage Earnings calendar Stock screener Stock lists Best stocks Markets Outlook Tools Data catalog Pricing Start free

Learn

Methodology Independent research Alternatives Glossary Learning paths Changelog Sample report FAQ

Research / Compare

Sectors Archetypes Outlook archive Compare stocks Alternatives Best stocks Stock screener Stock lists

Developers

Developers API docs Sandbox MCP launch status

Support Disclaimer Terms of service Privacy policy Editorial guidelines Corrections

Rating history

The rating each month's published research edition carried. A rating compares the price at analysis with the Fair value; it is not a record of whether the call was right.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026

Strong Buy